GERN vs. DVAX, FOLD, LGND, IRWD, MNKD, INVA, OPK, ALKS, ORGO, and INZY
Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Dynavax Technologies (DVAX), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), Innoviva (INVA), OPKO Health (OPK), Alkermes (ALKS), Organogenesis (ORGO), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical preparations" industry.
Geron (NASDAQ:GERN) and Dynavax Technologies (NASDAQ:DVAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.
Dynavax Technologies has higher revenue and earnings than Geron. Dynavax Technologies is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Geron currently has a consensus target price of $6.10, suggesting a potential upside of 60.53%. Dynavax Technologies has a consensus target price of $25.33, suggesting a potential upside of 136.10%. Given Dynavax Technologies' higher possible upside, analysts clearly believe Dynavax Technologies is more favorable than Geron.
Dynavax Technologies has a net margin of -2.75% compared to Geron's net margin of -38,730.00%. Dynavax Technologies' return on equity of -1.08% beat Geron's return on equity.
In the previous week, Dynavax Technologies had 9 more articles in the media than Geron. MarketBeat recorded 17 mentions for Dynavax Technologies and 8 mentions for Geron. Geron's average media sentiment score of 0.27 beat Dynavax Technologies' score of -0.11 indicating that Geron is being referred to more favorably in the media.
Geron received 13 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 69.52% of users gave Geron an outperform vote while only 65.82% of users gave Dynavax Technologies an outperform vote.
73.7% of Geron shares are owned by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are owned by institutional investors. 3.0% of Geron shares are owned by insiders. Comparatively, 3.0% of Dynavax Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Geron has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.
Summary
Dynavax Technologies beats Geron on 10 of the 18 factors compared between the two stocks.
Get Geron News Delivered to You Automatically
Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
